[Fecal microbiota transplantation for the treatment of intestinal disorders: An analysis of treatment of 15 000 patients].

粪便细菌疗法 粪便 移植 医学 胃肠病学 内科学 微生物学 生物 抗生素 艰难梭菌
作者
H L Tian,Lei Wang,C L,Bo Yang,Li Li,C Ye,Dongdong Zhao,Ziyang Lin,Jindong Cui,Yiwei Liu,Wei Zhu,Shen Zhou,N Li,Q Y Chen
出处
期刊:PubMed [National Institutes of Health]
卷期号:28 (3): 296-303 被引量:3
标识
DOI:10.3760/cma.j.cn441530-20250114-00025
摘要

Objective: To examine the long-term efficacy and complications of fecal microbiota transplantation (FMT) for the treatment of diseases related to intestinal dysbiosis. Methods: This was a retrospective descriptive study. Relevant data were collected from the records of 15 000 patients who had undergone FMT and been followed up for more than 3 months during the period from May 2017 to September 2024. The patient cohort comprised 3746 male and 11 254 female patients aged (45.3±12.2) years. The inclusion criterion was meeting the indications for FMT. Application of this criterion yielded 8258 patients with constipation, 684 with Clostridium difficile infection, 1730 with chronic diarrhea, 510 with inflammatory bowel disease, 432 with radiation enteritis, 1940 with irritable bowel syndrome, 365 with autism, 870 with postoperative gastrointestinal dysfunction, and 211 with neurodegenerative diseases. The three routes of delivering FMT comprised infusion of an enterobacterial solution through a nasoenteric tube into the jejunum for 6 consecutive days (upper gastrointestinal FMT group, 11 125 patients), oral intake of enterobacterial capsules for 6 consecutive days (oral capsule FMT, 3597 patients), and a single injection of a bacterial solution into the colon via colonoscopy (lower gastrointestinal FMT group, 278 patients). Other treatments were discontinued during the treatment and follow-up period and administration of other medications was not recommended unless absolutely necessary. The primary outcomes were the efficacy of FMT after 3, 12 and 36 months of treatment, and improvement in chronic constipation, C. difficile infection, chronic diarrhea, inflammatory bowel disease, radiation enteritis, irritable bowel syndrome, post-surgery gastrointestinal dysfunction, and autism. Other outcomes included the occurrence of short-term (within 2 weeks after treatment) and long-term (within 36 months after treatment) adverse reactions. Results: At 3, 12 and 36 months after treatment, the overall rates of effectiveness of treatment were 71.8% (10 763/15 000), 64.4% (7600/11 808) and 58.8% (3659/6218), respectively. Specifically, the rates of clinical improvement were 70.3% (5805/8258), 62.6% (3970/6345), and 56.5% (1894/3352), respectively, for constipation; 85.8% (587/684), 72.3% (408/564), and 67.3% (218/324), respectively, for C.difficile infection; 81.0% (1401/1730), 78.1% (1198/1534), and 72.3% (633/876), respectively, for chronic diarrhea; 64.3% (328/510), 52.3% (249/476), and 46.6 % (97/208), respectively, for inflammatory bowel disease; 77.3% (334/432), 65.4% (212/324), and 53.6% (82/153), respectively, for radiculitis; 70.6% (1370/1940), 64.5% (939/1456), and 60.4% (475/786), respectively, for irritable bowel syndrome; 75.3% (275/365), 70.0% (201/287), and 63.6% (112/176), respectively, for autism; 65.3% (568/870), 54.3% (355/654), and 46.5% (114/245), respectively, for post-surgical gastrointestinal dysfunction; and 45.0% (95/211), 40.5% (68/168), and 34.7% (34/98), respectively, for neurodegenerative diseases. At 3, 12, and 36 months post-treatment, clinical improvement rates were 77.1% (8580/11 125), 67.1% (6437/9595), and 62.1% (3196/5145), respectively, in the upper gastrointestinal route group; and 57.3% (2062/3597), 53.6% (1115/2081), and 45.0% (453/1006), respectively, in the oral capsule group; and 43.5% (121/278) , 36.4% (48/132) and 14.9% (10/67), respectively, in the lower gastrointestinal route group. No serious adverse reactions occurred during treatment or follow-up. The most common adverse reactions in the upper gastrointestinal route group, oral capsule group, and lower gastrointestinal route group were respiratory discomfort (20.4%, 2269/11 125), nausea and vomiting on swallowing the capsule (7.6%, 273/3597), and diarrhea (47.5%, 132/278), respectively; these symptoms resolved at the end of treatment. At 36 months of follow-up, 19 patients reported exacerbation of symptoms of pre-existing diseases and there had been 16 deaths that were not directly related to FMT. Additionally, no systemic diseases had developed after FMT. Conclusion: FMT for the treatment of intestinal dysfunction associated with disorders of the intestinal flora and related extraintestinal diseases is effective and not associated with serious adverse events.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
猪可以搞科研吗完成签到,获得积分10
1秒前
1秒前
爱学医的完成签到,获得积分10
2秒前
灰鸽子完成签到,获得积分10
2秒前
马马马发布了新的文献求助10
3秒前
4秒前
4秒前
4秒前
哈哈完成签到 ,获得积分10
4秒前
乐观冰薇完成签到,获得积分20
5秒前
小王完成签到,获得积分10
5秒前
震动的建辉完成签到,获得积分10
5秒前
symptom发布了新的文献求助10
6秒前
6秒前
Nicolesix发布了新的文献求助10
6秒前
6秒前
Nole的应助被湖心亭采纳,获得10
7秒前
单纯一笑发布了新的文献求助10
7秒前
平头发布了新的文献求助10
7秒前
梅夕阳发布了新的文献求助10
7秒前
英姑的应助被Purple采纳,获得10
8秒前
yyy发布了新的文献求助10
8秒前
9秒前
荆轲刺秦王完成签到 ,获得积分10
10秒前
家俊完成签到,获得积分10
11秒前
xxxx完成签到,获得积分20
11秒前
气凝前沿完成签到,获得积分10
11秒前
11秒前
11秒前
祁林林发布了新的文献求助10
11秒前
DagenLiu完成签到,获得积分10
11秒前
张张完成签到 ,获得积分10
12秒前
603完成签到,获得积分10
13秒前
小面包发布了新的文献求助10
13秒前
毛毛发布了新的文献求助10
14秒前
共享精神的应助被可靠诗蕊采纳,获得10
14秒前
2463841186的应助被鱼籽派采纳,获得10
14秒前
gala的夏天发布了新的文献求助10
15秒前
15秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Handbook of Sport Coaching Research 1000
Orthognathic Surgery - 2 Volume Set 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8193599
求助须知:如何正确求助?哪些是违规求助? 9579723
关于积分的说明 21867157
捐赠科研通 7793198
什么是DOI,文献DOI怎么找? 3437314
关于科研通互助平台的介绍 2560725
邀请新用户注册赠送积分活动 2484193